MMX - development of a rover locomotion system for Phobos

The MMX mission (Martian Moons eXploration) is a robotic sample return mission of the JAXA (Japan Aerospace Exploration Agency), CNES (Centre National d'Etudes Spatiales ) and DLR (German Aerospace Center) for launch in 2024. The mission aims to answer the question on the origin of Phobos and Deimos which will also help to understand the material transport in the earliest period of our solar system and the most important question how was the water brought on Earth. Besides the MMX mothership (JAXA) which is responsible for sampling and sample return to Earth a small rover which is built by CNES and DLR shall land on Phobos for in-situ measurements similar to MASCOT (Mobile Asteroid Surface Scout) on Ryugu. The MMX rover is a four wheel driven autonomous system with a size of 41 cm x 37 cm x 30 cm and a weight of approx. 25 kg. Multiple science instruments and cameras are integrated in the rover body. The rover body is basically a rectangular box, attached at the sides are four legs with one wheel per leg. When the rover is detached from the mothership, the legs are folded together at the side of the rover body. When the rover has landed passively (no parachute, braking rockets) on Phobos, the legs are autonomously controlled to bring the rover in an upright orientation. One Phobos day lasts 7 earth hours, which gives for the total mission time of 3 earth months, the number of about 300 extreme temperature cycles. These cycles and the wide span of surface temperature between day and night are main design drivers for the rover. This paper gives a short overview on the MMX mission, the MMX rover and a detailed view on the development of the MMX rover locomotion subsystem

Safety and applicability of a pre-stage public access ventilator for trained laypersons: a proof of principle study

Abstract Background Contemporary resuscitation guidelines for basic life support recommend an immediate onset of cardiac compressions in case of cardiac arrest followed by rescue breaths. Effective ventilation is often omitted due to fear of doing harm and fear of infectious diseases. In order to improve ventilation a pre-stage of an automatic respirator was developed for use by laypersons. Methods Fifty-two healthy volunteers were ventilated by means of a prototype respirator via a full-face mask in a pilot study. The pre-stage public access ventilator (PAV) consisted of a low-cost self-designed turbine, with sensors for differential pressure, flow, FO2, FCO2 and 3-axis acceleration measurement. Sensor outputs were used to control the respirator and to recognize conditions relevant for efficiency of ventilation and patients’ safety. Different respiratory manoeuvres were applied: a) pressure controlled ventilation (PCV), b) PCV with controlled leakage and c) PCV with simulated airway occlusion. Sensor signals were analysed to detect leakage and airway occlusion. Detection based upon sensor signals was compared with evaluation based on clinical observation and additional parameters such as exhaled CO2. Results Pressure controlled ventilation could be realized in all volunteers. Leakage was recognized with 93.5% sensitivity and 93.5% specificity. Simulated airway occlusion was detected with 91.8% sensitivity and 91.7% specificity. Conclusion The pre-stage PAV was able to detect potential complications relevant for patients’ safety such as leakage and airway occlusion in a proof of principle study. Prospectively, this device provides a respectable basis for the development of an automatic emergency respirator and may help to improve bystander resuscitation

Exhaled volatile substances mirror clinical conditions in pediatric chronic kidney disease

<div><p>Monitoring metabolic adaptation to chronic kidney disease (CKD) early in the time course of the disease is challenging. As a non-invasive technique, analysis of exhaled breath profiles is especially attractive in children. Up to now, no reports on breath profiles in this patient cohort are available. 116 pediatric subjects suffering from mild-to-moderate CKD (n = 48) or having a functional renal transplant KTx (n = 8) and healthy controls (n = 60) matched for age and sex were investigated. Non-invasive quantitative analysis of exhaled breath profiles by means of a highly sensitive online mass spectrometric technique (PTR-ToF) was used. CKD stage, the underlying renal disease (HUS; glomerular diseases; abnormalities of kidney and urinary tract or polycystic kidney disease) and the presence of a functional renal transplant were considered as classifiers. Exhaled volatile organic compound (VOC) patterns differed between CKD/ KTx patients and healthy children. Amounts of ammonia, ethanol, isoprene, pentanal and heptanal were higher in patients compared to healthy controls (556, 146, 70.5, 9.3, and 5.4 ppbV vs. 284, 82.4, 49.6, 5.30, and 2.78 ppbV). Methylamine concentrations were lower in the patient group (6.5 vs 10.1 ppbV). These concentration differences were most pronounced in HUS and kidney transplanted patients. When patients were grouped with respect to degree of renal failure these differences could still be detected. Ammonia accumulated already in CKD stage 1, whereas alterations of isoprene (linked to cholesterol metabolism), pentanal and heptanal (linked to oxidative stress) concentrations were detectable in the breath of patients with CKD stage 2 to 4. Only weak associations between serum creatinine and exhaled VOCs were noted. Non-invasive breath testing may help to understand basic mechanisms and metabolic adaptation accompanying progression of CKD. Our results support the current notion that metabolic adaptation occurs early during the time course of CKD.</p></div

Exhaled alveolar concentrations of selected VOC in the study population.

<p>Exhaled alveolar concentrations of selected VOC in the study population.</p

Heat map (A) and PCA score (B) obtained in CKD patients (n = 56) and controls (n = 60).

<p>A: Heat map based on normalized data of 71 mass traces (18 to 373 m/z) in breath of CKD patients (left) and healthy controls (right). Regions with elevated breath VOC levels are shown as red and yellow boxes for patients and controls, respectively. B: PCA score plot (PC-1 vs. PC-2) of healthy controls (blue squares, n = 60) and CKD patients (red dots, n = 56). Red circles represent data from patients with a functional renal transplant.</p

Exhaled alveolar concentrations of isoprene relative to the BMI in controls (blue circles) and patients (red circles).

<p>Controls (n = 60): r = 0.53, p < 0.001; patients (n = 56): r = 0.47, p<0.001.</p

Clinical characteristics of patients.

<p>Data is given as median and range. Superscripts denote significant differences between identically labelled groups.</p

Anthropometric data of the study population and relevant medications in CKD patients.

<p>Anthropometric data of the study population and relevant medications in CKD patients.</p

Schematic description of continuous real-time breath analysis.

<p>a) Participants breathed through a sterile mouthpiece without resistance. Ex- and inhaled breath was transferred continuously into the heated transfer line (connected via t-piece) of the PTR-ToF-MS in a side-stream mode at a flow of 20 ml/min. b) Every 200 ms a TOF—mass spectrum was recorded. c) Profiles of breath VOCs could be recorded continuously and in a phase resolved way. Acetone (red curve 59.049 m/z—as endogenous, blood borne VOC) was used to track breath phases and to assign all other mass traces to alveolar (red areas) and inhalation (blue areas) phases. In this way, intensities of VOCs other than acetone, such as isoprene (pink curve, 69.070 m/z) or dimethyl sulfide (blue curve, 63.026 m/z) could be assigned to the different breath phases and quantified in alveolar and inspiratory air.</p

Exhaled alveolar concentrations of ammonia, ethanol, methylamine, isoprene, pentanal and heptanal relative to the eGFR in CKD patients (n = 56).

<p>Exhaled alveolar concentrations of ammonia, ethanol, methylamine, isoprene, pentanal and heptanal relative to the eGFR in CKD patients (n = 56).</p